CHANGES IN THE CONCENTRATION OF UROLATIASIS MARKERS DEPENDING ON STONE-FORMING ACTIVITY IN PATIENTS WITH RECURRENT UROLATIASIS
- Authors: Kamalov A.A1, Okhobotov D.A1, Nizov A.N1
-
Affiliations:
- Lomonosov MSU
- Issue: No 1 (2018)
- Pages: 15-19
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/322058
- DOI: https://doi.org/10.18565/urol.2018.1.15-19
- ID: 322058
Cite item
Open Access
Access granted
Abstract
The study aimed to investigate the changes in the concentration of bikunin, osteopontin, and nephrocalcin, depending on the changes in the renal stone-forming activity in patients with recurrent urolithiasis. Materials and methods. The study comprised 152 patients with recurrent calcium oxalate stones at various localizations. Patients of the study group (n=78) were administered complex preventive treatment (water load, Blamaren, thiazide diuretics, oral calcium supplementation) aimed at reducing the activity of urolithiasis. Patients of the control group (n=74) received no treatment. The studied parameters included concentrations of urine bikunin, osteopontin, and nephrocalcin in using ELISA. The follow-up period was six months. Results. By the end of the follow-up, the bikunin concentration in the control group was significantly higher than in the study group (7.0±0.81 mg/ml vs. 3.28±0.86 mg/ml, respectively, p<0.05) while osteopontin level was significantly lower (2.4±0.39 mg/ml vs. 3.4±0.36 mg/ml, p<0.05). The nephrocalcin concentrations during the follow-up period did not change significantly (p>0.05). The presence of hypercalciuria did not lead to significant changes in the concentration of stone formation inhibitors. Discussion. The increase in bikunin concentration in control patients is associated with an increase in the expression of this stone formation inhibitor due to the rise in the urolithiasis activity. Reduction in the osteopontin concentration in patients with high urolithiasis activity is a consequence of osteopontin being a constituent of calcium oxalate stones. Conclusion. In patients with calcium oxalate urolithiasis, testing for urine concentrations of bikunin and osteopontin as potential markers can be used to estimate the risk of stone recurrence.
Full Text
About the authors
A. A Kamalov
Lomonosov MSU
Email: armais.kamalov@rambler.ru
Academician of the RAS, Dr.Med.Sci., Prof., Director of the Medical Research and Educational Center; Head of the Department of Urology and Andrology, Faculty of Fundamental Medicine Moscow, Russia
D. A Okhobotov
Lomonosov MSU
Email: 14032007m@gmail.com
Ph.D., Urologist and Senior Researcher at the Research Department of Urology and Andrology of the of the Medical Research and Educational Center; Scientific Secretary of the Russian Society «Men’s Health» Moscow, Russia
A. N Nizov
Lomonosov MSU
Email: nizovale@gmail.com
Urologist at the Medical Research and Educational Center; Ph.D. Student at the Faculty of Fundamental Medicine Moscow, Russia
References
- Alyaev Yu.G., Amosov A.V., Saenko V.S. Metaphylaxis of urolithiasis. M.: Eksmo. 2007. 350 p. Russian (Аляев Ю.Г., Амосов А.В., Саенко В.С. Метафилактика мочекаменной болезни. М.: Эксмо. 2007. 350 с.).
- Barbera M. The importance of citrates in treatment and prophylaxis of calcium oxalate urinary stones. Arch Ital Urol Androl. 2016;88(4):343-44. doi: 10.4081/aiua.2016.4.343.
- Coe F.L., Worcester E.M. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;2(9):519-533. doi: 10.1038/nrneph.2016.101. Epub 2016 Jul 25.
- Holmes R.P., Knight J., Assimos D.G. Lowering urinary oxalate excretion to decrease calcium oxalate stone disease. Urolithiasis. 2016;44(1):27-32. doi: 10.1007/s00240-015-0839-4. Epub 2015 Nov 27.
- Wolfgram D.F., Gundu V., Astor B.C., Jhagroo R.A. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Urolithiasis. 2013;41(4):315-22. doi: 10.1007/s00240-013-0568-5. Epub 2013 May 10.
- Donald Smith Urology. Edited by E. Tanago and J. McAninch. M., Praktika. 2005. 819 p. Russian (Урология по Дональду Смиту. Под редакцией Э. Танаго и Дж. Маканича. М., Практика. 2005. 819 с.).
- Zharikov A.Y., Motin Y.G., Zverev Y.F., Lampatov V.V., Bryukhanov V.M., Talalaeva O.S. Expression of renal crystallization inhibitors in experimental nephrolithiasis. Bull Exp Biol Med. 2012; 153(2):279-282.
- Lulich J.P., Osborne C.A., Carvalho M., Nakagawa Y. Effects of a urolith prevention diet on urine compositions of glycosaminoglycans, Tamm-Horsfall glycoprotein, and nephrocalcin in cats with calcium oxalate urolithiasis. Am J Vet Res. 2012;73(3):447-451. doi: 10.2460/ajvr.73.3.447.
- Phillips R., Hanchanale V.S., Myatt A., Somani B., Nabi G., Biyani C.S. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;(10):CD010057. doi: 10.1002/14651858.CD010057.pub2.
- Robertson W.G. Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease. Urolithiasis. 2016;44(1):9-26. doi: 10.1007/s00240-015-0849-2. Epub 2015 Dec 8. Review.
- Malihi Z., Wu Z., Stewart A.W. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016;104(4):1039-1051. Epub 2016 Sep 7.
- Kustov A.V., Moryganov M.A. Quantitative mineralogical analyzes of kidney stones and diagnosing metabolic disorders in female patients with calcium oxalate urolithiasis. Urologiia. 2016;(1):11-15.
- Li X., Liu K., Pan Y., Zhang J., Lv Q., Hua L., Wang Z., Li J., Yin C. Roles of Osteopontin Gene Polymorphism (rs1126616), Osteopontin Levels in Urine and Serum, and the Risk of Urolithiasis: A MetaAnalysis. Biomed Res Int. 2015:315043. doi: 10.1155/2015/315043. Epub 2015 Feb 15. Review.
- Mohebbi N., Ferraro P.M., Gambaro G., Unwin R. Tubular and genetic disorders associated with kidney stones. Urolithiasis. 2017;45(1):127-137. doi: 10.1007/s00240-016-0945-y. Epub 2016 Nov 28. Review.
Supplementary files
